ericsphotography-istockphoto-com-us-gavel-2-1
ericsphotography / iStockphoto.com
15 October 2018Americas

Federal Circuit upholds two patent decisions over Copaxone

The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone (glatiramer acetate) 40mg/mL treatment are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Big Pharma
28 May 2014   Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.

More on this story

Big Pharma
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Big Pharma
28 May 2014   Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.

More on this story

Big Pharma
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Big Pharma
28 May 2014   Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.